Cargando…

Erratum: Oncolytic viruses: a new class of immunotherapy drugs

Detalles Bibliográficos
Autores principales:	Kaufman, Howard L., Kohlhapp, Frederick J., Zloza, Andrew
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2016
Materias:	Erratum
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7608450/ https://www.ncbi.nlm.nih.gov/pubmed/30907381 http://dx.doi.org/10.1038/nrd.2016.178

Ejemplares similares

Oncolytic viruses: a new class of immunotherapy drugs
por: Kaufman, Howard L., et al.
Publicado: (2015)

Oncolytic Viruses—Natural and Genetically Engineered Cancer Immunotherapies
por: Jhawar, Sachin R., et al.
Publicado: (2017)

Oncolytic virus immunotherapy induces immunogenic cell death and overcomes STING deficiency in melanoma
por: Bommareddy, Praveen K., et al.
Publicado: (2019)

Acute viral infection results in a PD-1-dependent loss of anti-tumor CD8+ T cell responses: implications for tumor immunotherapy
por: Kohlhapp, Frederick, et al.
Publicado: (2015)

Single-step nanoparticle antigen presentation system for tumor immunotherapy
por: Kohlhapp, Frederick, et al.
Publicado: (2015)

Erratum to: Oncolytic virus efficiency inhibited growth of tumour cells with multiple drug resistant phenotype in vivo and in vitro
por: Goncharova, Elena P., et al.
Publicado: (2016)

Oncolytic Viruses and Hematological Malignancies: A New Class of Immunotherapy Drugs
por: Innao, Vanessa, et al.
Publicado: (2020)

Immunoglobulin-like transcript 2 (ILT2) is a biomarker of therapeutic response to oncolytic immunotherapy with vaccinia viruses
por: Zloza, Andrew, et al.
Publicado: (2014)

Combination immunotherapy with anti-CTLA-4 and interleukin-2 redirects regulatory T cells into tumor-draining lymph nodes and expands anti-tumor CD8+ T cells in the tumor microenvironment
por: Broucek, Joseph, et al.
Publicado: (2014)

Treatment of a stage III rima glottidis patient with the oncolytic virus Rigvir: A retrospective case report: Erratum
Publicado: (2019)

Two roads for oncolytic immunotherapy development
por: Kaufman, Howard L., et al.
Publicado: (2019)

Erratum to: Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of bladder carcinoma
por: Kamat, Ashish M., et al.
Publicado: (2017)

Erratum for Mor et al., “Identification of a New Class of Antifungals Targeting the Synthesis of Fungal Sphingolipids”
por: Mor, Visesato, et al.
Publicado: (2018)

Erratum to: Immunotherapy in endometrial cancer - an evolving therapeutic paradigm
por: Longoria, Teresa C., et al.
Publicado: (2016)

Erratum to: Allergen immunotherapy for allergic rhinoconjunctivitis: protocol for a systematic review
por: Dhami, Sangeeta, et al.
Publicado: (2017)

Erratum to: Impact of New Genomic Technologies on Understanding Adverse Drug Reactions
por: Maggo, Simran D. S., et al.
Publicado: (2016)

Oncolytic Virus Immunotherapy
por: Marchini, Antonio, et al.
Publicado: (2021)

Erratum to Assays for predicting and monitoring responses to lung cancer immunotherapy
por: Teixidó, Cristina, et al.
Publicado: (2015)

Erratum to: Saliva Versus Plasma Bioequivalence of Rusovastatin in Humans: Validation of Class III Drugs of the Salivary Excretion Classification System
por: Idkaidek, Nasir, et al.
Publicado: (2015)

Erratum to: Allergen immunotherapy for allergic asthma: protocol for a systematic review
por: Dhami, Sangeeta, et al.
Publicado: (2017)

Attenuated Dengue virus PV001-DV induces oncolytic tumor cell death and potent immune responses
por: Goldufsky, Josef W., et al.
Publicado: (2023)

Erratum to: Consensus classification of human leukocyte antigen class II proteins
por: Saha, Indrajit, et al.
Publicado: (2013)

Erratum to: Singing classes for chronic obstructive pulmonary disease: a randomized controlled trial
por: Lord, Victoria M, et al.
Publicado: (2014)

Erratum to: Safety and feasibility of oral immunotherapy to multiple allergens for food allergy
por: Bégin, Philippe, et al.
Publicado: (2016)

Oncolytic Viruses: Immunotherapy Drugs for Gastrointestinal Malignant Tumors
por: Li, Qingbo, et al.
Publicado: (2022)

Erratum to: Allergen immunotherapy for insect venom allergy: protocol for a systematic review
por: Dhami, Sangeeta, et al.
Publicado: (2017)

Erratum: Evaluation of a new, rapid, simple test for the detection of influenza virus
por: Hurtado, Juan Carlos, et al.
Publicado: (2015)

Development of a new fusion-enhanced oncolytic immunotherapy platform based on herpes simplex virus type 1
por: Thomas, Suzanne, et al.
Publicado: (2019)

Erratum: Zika Virus Disease
Publicado: (2017)

Cytomegalovirus Infection in Ireland: Seroprevalence, HLA Class I Alleles, and Implications: Erratum
Publicado: (2016)

Erratum to: Debates in allergy medicine: specific immunotherapy efficiency in children with atopic dermatitis
por: Slavyanskaya, Tatiana A., et al.
Publicado: (2016)

Erratum to neoadjuvant chemo-immunotherapy for lung cancer: how much is too much?
Publicado: (2023)

Erratum: Emerging/re-emerging viral diseases & new viruses on the Indian horizon
Publicado: (2019)

Fusogenic Viruses in Oncolytic Immunotherapy
por: Krabbe, Teresa, et al.
Publicado: (2018)

Oncolytic viruses for cancer immunotherapy
por: Hemminki, Otto, et al.
Publicado: (2020)

Measles Virus as an Oncolytic Immunotherapy
por: Engeland, Christine E., et al.
Publicado: (2021)

Erratum to: Autologous tumor lysate/Bacillus Calmette–Guérin immunotherapy as an adjuvant to conventional breast cancer therapy
por: Convit, J., et al.
Publicado: (2016)

Erratum to: Rhesus macaque MHC class I molecules show differential subcellular localizations
por: Rosner, Cornelia, et al.
Publicado: (2010)

Erratum: New Developments at EHP
Publicado: (2015)

Erratum to: Combined therapy with oncolytic adenoviruses encoding TRAIL and IL-12 genes markedly suppressed human hepatocellular carcinoma both in vitro and in an orthotopic transplanted mouse model
por: El-Shemi, Adel Galal, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_k9edi71ju5htcen51g4q757coa